Fig. 4

Assessment of the nature of non-proportional hazards when patients’ with ILC are opposed to IDC using the Schoenfeld Residuals Test; ILC invasive lobular carcinoma, IDC invasive ductal carcinoma, DFS disease free survival, OS overall survival